\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[authoryear]{natbib}



\newif\ifnokeywords\nokeywordsfalse

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}
\let\@issuelogo\@empty%
\let\@issuelogoex\@empty%
\def\issuelogo#1{\gdef\@issuelogo{#1}}
\def\issuelogoex#1{\gdef\@issuelogoex{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}
\lefthyphenmin = 3

\def\title#1{%
  \gdef\@title{%
      \vspace*{-40pt}%
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%%{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}\hfill
         \mbox{~}\hspace{5pt}\parbox{.1\linewidth}{\IfFileExists{images/\@issuelogo.\@issuelogoex}{\includegraphics[width=79pt,height=61pt]{images/\@issuelogo.\@issuelogoex}}{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}}\hfill
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
          \begin{center}\fontsize{17}{17}\selectfont\scshape\vskip-7pt International Journal of Research in Pharmaceutical Sciences\hfill\end{center}%
          \vspace*{-10pt}\hspace*{4pt}{\fontsize{8}{9}\selectfont Published by JK Welfare \& Pharmascope Foundation\hfill  Journal Home Page: \href{www.ijrps.com}{\color{blue}\underline{\smash{www.ijrps.com}}}}\hspace*{4pt}\mbox{}}}%
       \par\vspace*{-1pt}\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}

\def\abbrvJournalTitle{Int. J. Res. Pharm. Sci.}

\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}

                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
%\def\bibjtitle#1{#1}   %%Publisher request
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}

\makeatother
\date{}


\begin{document}


\def\RunningAuthor{Ezhilarasan D et al.}
\firstPage{701}
\articleType{Original Article}
\receivedDate{01 Aug 2020}
\acceptedDate{07 Sep 2020}
\revisedDate{01 Sep 2020}
\journalVolume{2020, 11 (SPL)}
\journalIssue{1}
\journalDoi{ijrps.v11iSPL1.3069}
\copyrightYear{2020}
\def\authorCount{3}
\def\affCount{1}

\def\journalTitle{International Journal of Research in Pharmaceutical Sciences}

\title{Impact of Covid 19 in Liver Disease Patients}
\author{Kameswari~S,  
            Lakshmi~T, 
            Ezhilarasan~D\textsuperscript{*}~\\[5pt]{Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS),  Saveetha University, Chennai-77, Tamil Nadu, India}}

\begin{abstract}
The coronavirus 2019 (covid 19) represents a dispute to human services in infected regions. Aged people with comorbidity complications have been found with a high risk of severity in infection prevalence. A comprehensive search in PUBMED, GOOGLE SCHOLAR using the keywords - coronavirus, liver impairment, anosmia and ageusia, upper and lower respiratory infection, liver metabolism. This analysis helps in understanding how COVID 19 affected patients with liver disease and their impacts. Several studies reported about the impact of liver in COVID 19, thus COVID 19 is influencing the liver in a massive way by inducing the changes in normal liver and aggregating the existing liver disease. 
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}Coronavirus,\newline liver impairment,\newline anosmia and ageusia,\newline upper and lower respiratory infection,\newline liver metabolism
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright\textsuperscript{*}Corresponding Author\par Name:\ Ezhilarasan~D~\\ Phone:\ ~\\  Email:\ ezhilarasan.sdc@saveetha.com
        \par}\vspace*{-11pt}\hrulefill\par{\fontsize{12}{14}\selectfont ISSN: 0975-7538}\par% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-11pt}\hrulefill\\{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\par{IJRPS |~\href{www.ijrps.com}{www.ijrps.com}}\par%
        \vspace*{-2pt}{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\par%
        \vspace*{-11pt}\rule{\linewidth}{1.2pt}
        \makeatother
        
    
\section{Introduction}
Coronavirus is an infectious illness that has been quickened around the world. COVID 19 is caused by differentiated late coronavirus, as SARS COV 2. It recently happened in Wuhan, China \unskip~\citep{869201:20179134}. The mode of virus transmission is mostly through aerosols, droplets infection of infected patients \unskip~\citep{869201:20179147}. The infections are round or pleomorphic with wrapped particles. Severe respiratory distress syndrome incites a huge scope starting in China, and the Corona infections have become the significant pathogens of developing respiratory illness. The most objective organ is the lungs \unskip~\citep{869201:20179145}. A portion of the indications incorporate the breath, headaches, nasal block, sore throat and so on., while manifestations stay over the span of contamination in most patients. More settled patients were recognised at the higher danger of deadly infection with hypertension, increased sugar level, heart diseases being the most incessant comorbidities in these cohorts \unskip~\citep{869201:20179143}. The indications of the starting periods of the infection are vague. The death rates for cases all around stay between 1\% to 2\%. Rapid multiplication of infections is additionally an entangled factor in identifying the ailment. Consequently the recognition of this sickness can be distinguished by different strategies like Real time - polymerase Chain Reaction, Computed tomography and so forth{\ldots}Apart from lungs, the liver is also one of the highly infected organs for COVID infection. Therefore, this review focuses on the impact of COVID 19 infection on the liver and in patients with liver diseases.

\textbf{Covid 19 and the liver}

Liver impact in patients with COVID 19 diseases may be straightforwardly brought about by the viral contaminations of liver cells. Roughly 2-10\% of patients with COVID 19 present with looseness of the bowels and SARS-CoV2 RNA have been recognized in stool tests. This confirmation implicates the opportunity of viral presentation in the liver. Both the SARS-CoV2 and the SARS - CoV to the angiotens in change over catalysts 2 (ACE2) receptor to enter the objective cell, where the infection recreates and infects other cells in the upper respiratory tract and lung tissues. It is said that the liver disability might be because of drug hepatotoxicity but in safe - intervened aggravation, for instance, cytokines storm and pneumonia - related hypoxia may likewise add to liver injury or even form into liver dissatisfaction in patients with COVID 19 who are critically sick. Liver damage in mild cases of corona infection is frequently transient and returns to normal without any special treatment. A portion of the effects of the liver are raised alanine aminotransferase (ALT) levels, lesser platelet counts and decreased albumin level at the hour of affirmation have been related with higher mortality \unskip~\citep{869201:20179144}. Decreased platelets counts, climbing neutrophil counts, low albumin level and also with high ferritin levels \unskip~\citep{869201:20179146}. Possibly patients with chronic liver disease are at high risk of infectious due to cirrhosis related immune dysfunction \unskip~\citep{869201:20179148,869201:20179154}. Elevated aspartate aminotransferase (AST) and ALT with slightly bilirubin levels ranging from 14\% to 52\% is also the impact associated with liver \unskip~\citep{869201:20179133}. The elevated serum ALT has also been reported in liver diseased patients hospitalised for COVID 19 \unskip~\citep{869201:20179142}. Liver function tests which are done for differentiated duration are examined with no evidence but with greater liver function derangement \unskip~\citep{869201:20179139}. 

A few potential parts are shown as beneath. a) Immune mediated damage because of the serious reaction following COVID-19 infection: the disturbance biomarkers including C receptor protein (CRP), serum ferritin, LDH, D-dimer, IL-6, IL-2, were essential brought up in extraordinary patients with COVID-19 \unskip~\citep{869201:20179149} b) Direct cytotoxicity as a result of dynamic viral replication in hepatic cells: SARS-CoV-2 association with target cells through ACE2. Since angiotensin-converting enzyme two is communicated richly in the liver and explicitly on biliary epithelial cells, the liver is a possible goal for the diseases \unskip~\citep{869201:20179135}, which was anyway not yet illustrated. c) Anoxia: the sign of COVID-19 is respiratory frustrations. Hypoxic hepatitis by virtue of anoxia are in extreme cases. d) Drug actuated liver damage (DALI): starting clinical standard prescription antiviral administrator for COVID-19, with some of them, including ritonavir, chloroquine, tocilizumab, chinese standard prescription being possibly hepatotoxic in certain patients. e) Reactivation of prior liver infection: patients with past incessant liver illness, may be increasingly powerless to liver disease from SARS-CoV-2 \unskip~\citep{869201:20179136}. 

Natural medications like tocilizumab and baricitinib may likewise cause hepatitis B reactivation and therefore lead to liver capacity crumbling.

A portion of the suggestions for the administration of liver damage during COVID 19 are


  
  \begin{enumerate}
  \item \relax Ordinary perception of liver biochemistries should be followed up on in all COVID 19 patients. 
  \item \relax Indication of anomalous liver biochemistries doesn't seek to represent a contraindication utilizing researched or off mark therapeutics for COVID 19 , although strict checking is advisable.
  \item \relax Serological screening test for hepatitis B and C examination of different reasons for the liver infection, which ought to be taken into the neighborhood study of disease transmission, is advocated while evaluating patients with COVID 19 and raised liver biochemistries \unskip~\citep{869201:20179141}.
  \end{enumerate}
  \textbf{Reduction of visible exposure }

Safety measures are strictly followed with social distancing as there are currently no vaccines thus the strict infection control is needed physical distancing has been suggested to implement in many countries. Thus these measures aim at preventing a rapid increase in COVID 19 infection in the general population \unskip~\citep{869201:20179150}. A portion of the standard working methodology for outpatient care including rebuilding of long holding up regions to permit adequate separation between patients, decrease of waiting times and direct contact with the persons is the reason for the doctor-patient relationships and allows the doctor to find the complete conditions of the patients. Thus, the COVID 19 is said to be pandemic, so people are asked to stay quarantined at home and also to take care of them from harmful infections and explain the future treatment.

\textbf{Impact of covid on patients with compensated liver diseases}

Ceaseless viral hepatitis doesn't seem to expand the danger of an extreme course of COVID 19 \unskip~\citep{869201:20179155}. Patients who are non-alcoholic with liver illness or steatohepatitis may experience the ill effects of metabolic comorbidities for example, diabetes, hypertension and stoutness may face the expanded danger of extreme course of COVID 19. Patients having immune system liver infections are guided with immunosuppressive treatment. Patients having compensated cirrhosis of liver are considered with postponing hepatocellular carcinoma and screening for differences \unskip~\citep{869201:20179151}. Listing up for transplantation ought to be limited to patients with poor transient visualization with intense on constant liver diseases and also to highlight on the significance of immunization for streptococcus pneumoniae and flu.

\textbf{Liver related diagnostic procedure}

Patients having COVID 19 can experience endoscopic technique, yet there is a serious danger of spreading SARS COV 2 \unskip~\citep{869201:20179137}. During Esophagogastroduodenoscopy, spreading of infection containing beads can happen. In this manner, for COVID 19 patients, endoscopy can be utilized in crises, for example, gastric intestinal tract draining conditions \unskip~\citep{869201:20179138}. Systemic aggravation related with COVID 19 will cloud etiology explicit histology attributes \unskip~\citep{869201:20179153}. Liver biopsy may speak to hazards for viral transmission. Remdevivir goes about as an adenosine that produces RNA chain end, and ritonavir supported lopinavir gave some antiviral consequences for SARS-COV in vitrogen study and no treatment \unskip~\citep{869201:20179152}. Certain immunosuppressive medicines where drug levels of cyclosporine, sirolimus will be firmly checked \unskip~\citep{869201:20179140}. In patients with liver sickness and hazard factors for an extreme danger of COVID 19 diseases, we can recommend the incorporation into early antiviral treatment programs or clinical preliminaries that may be dynamic at different regions. Patients having interminable liver malady, bacterial peritonitis, Hepatocellular carcinoma, locoregional treatments are suggested.
    
\section{Conclusion}
COVID 19 infection aggravates hepatic diseases with a severe damage which is predominantly a clinical distraction. The impact of COVID 19 in liver disease patients is very hazardous. Consequently, clinicians should concentrate the viral control and regulate the inborn immune dysfunction in COVID 19 in liver infected patients.
\section*{Acknowledgement}The authors are thankful to Saveetha Dental College for providing a platform to express over knowledge.

\textbf{Conflict of interest}

The authors declare that they have no conflict of interest for this study.

\textbf{Funding support}

The authors declare that they have no funding support for this study.
    

\bibliographystyle{pharmascope_apa-custom}

\bibliography{\jobname}
\end{document}
